News stories about Sarepta Therapeutics (NASDAQ:SRPT) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sarepta Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.5434497569883 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- You Can’t Reason With a Steamroller (finance.yahoo.com)
- Sarepta is making a bold bet on genetic medicine (finance.yahoo.com)
- Active Stock Evaluation – Sarepta Therapeutics, Inc. (NASDAQ: SRPT) – Alpha Beta Stock (alphabetastock.com)
- Sarepta Therapeutics: Continued Upside In 2018 – Seeking Alpha (seekingalpha.com)
- Sarepta Therapeutics, Inc. (SRPT) Swings under Short-Term Obligation – Stock News Stop (stockmarketstop.com)
Several equities analysts recently weighed in on the stock. Janney Montgomery Scott assumed coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 3rd. They set a “buy” rating and a $75.00 price objective on the stock. HC Wainwright set a $75.00 price objective on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Zacks Investment Research lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. Oppenheimer reaffirmed a “buy” rating and set a $76.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. Finally, UBS Group reaffirmed an “outperform” rating and set a $56.51 price objective (down previously from $76.00) on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and seventeen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $63.88.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up $2.53 during trading on Friday, hitting $61.52. 2,217,100 shares of the stock traded hands, compared to its average volume of 1,700,000. The firm has a market capitalization of $3,980.00, a P/E ratio of -30.16 and a beta of 1.37. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44. Sarepta Therapeutics has a twelve month low of $26.26 and a twelve month high of $61.89.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.66. The business had revenue of $45.95 million for the quarter, compared to the consensus estimate of $41.29 million. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. During the same quarter last year, the company posted ($0.95) earnings per share. analysts anticipate that Sarepta Therapeutics will post -3.07 earnings per share for the current year.
In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the sale, the director now owns 13,333 shares in the company, valued at $745,181.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Douglas S. Ingram purchased 38,138 shares of the firm’s stock in a transaction on Wednesday, November 8th. The shares were acquired at an average price of $52.44 per share, for a total transaction of $1,999,956.72. Following the purchase, the chief executive officer now directly owns 420,196 shares of the company’s stock, valued at $22,035,078.24. The disclosure for this purchase can be found here. Company insiders own 9.60% of the company’s stock.
WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Sarepta Therapeutics (SRPT) Stock Price” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://ledgergazette.com/2018/01/13/sarepta-therapeutics-srpt-earns-daily-coverage-optimism-score-of-0-18.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.